Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs Vanguard Total Stock Market Index Fund ETF (VTI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spyre Therapeutics Inc. Common Stock vs Vanguard Total Stock Market Index Fund ETF — how do they compare? Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B), while Vanguard Total Stock Market Index Fund ETF trades at $375.54 (market cap $2.30T). The key difference: Vanguard Total Stock Market Index Fund ETF is far larger — about 305.9× Spyre Therapeutics Inc. Common Stock's market cap, and Vanguard Total Stock Market Index Fund ETF is trading nearer its 52-week high, Spyre Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Spyre Therapeutics Inc. Common Stock for 0 Days and Vanguard Total Stock Market Index Fund ETF for 132 Days on average.
| SYRE | VTI | |
|---|---|---|
Market Cap | $7.52B | $2.30T |
Volume | 1,441,031 | 2,460,185 |
Sector | Health | — |
52-Week High | $108.92 | $384.30 |
52-Week Low | $22.18 | $311.68 |
Typical Hold Time | 0 Days | 132 Days |
Enterprise Value | $6.52B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
VTI trades at $381.32, down slightly by 0.07% today, with a bullish technical signal driven by strong moving average alignment. The ETF offers broad U.S. equity exposure, though key financial ratios are not provided in the data. Recent news highlights its appeal for long-term investors seeking diversification and low-cost market access.
The outlook remains positive given strong technical momentum and media optimism, but risks include market concentration in top holdings and broader economic volatility. Investors benefit from VTI's extensive diversification, yet should monitor allocation weights and macroeconomic trends for potential impacts on returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →About Vanguard Total Stock Market Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the index, which represents approximately 100% of the investable US stock market and includes large-, mid-, small-, and micro-cap stocks. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the full index in terms of key characteristics.
Read more on VTI →
